Results 161 to 170 of about 767,969 (287)

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. [PDF]

Hemasphere
Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Flores LB, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Wang J, Loghavi S, Su X, DiNardo CD, Delwel R, Bhalla KN.   +23 more
europepmc   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. [PDF]

Leukemia
Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN.   +17 more
europepmc   +1 more source

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. [PDF]

Front Oncol, 2022
Garcia PL, Miller AL, Zeng L, van Waardenburg RCAM, Yang ES, Yoon KJ.   +5 more
europepmc   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch, Markus Matilainen, Giulia N. Baldrighi, Marjo Nylund, Maija Saraste, Laura Airas   +5 more
wiley   +1 more source

The Selective Bromodomain and Extra-Terminal Domain (BET) Inhibitor RVX-208 Reduces Cocaine-Seeking Behaviour and Alters Proteomic Pathways in the Nucleus Accumbens. [PDF]

Addict Biol
Sacko TJ, Seyednejad A, Engelhardt J, Sartor GC.   +3 more
europepmc   +1 more source

Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. [PDF]

Br J Cancer, 2022
Tontsch-Grunt U, Traexler PE, Baum A, Musa H, Marzin K, Wang S, Trapani F, Engelhardt H, Solca F.   +8 more
europepmc   +1 more source

Natural Frequencies of Levodopa‐Induced Dyskinesia in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Abnormal involuntary movements, known as dyskinesias, are common complications of levodopa treatment in patients with Parkinson's disease and can significantly impair quality of life. The underlying pathophysiology remains unclear, and current therapeutic options are limited.
Ioannis U. Isaias, Federica Avantaggiato, Gianni Pezzoli, Andrea Canessa   +3 more
wiley   +1 more source

BET Inhibitor JQ1 Attenuates Atrial Fibrillation Through Modulation of Fibrosis, Calcium Homeostasis, and Mitochondrial Function in a Murine Model. [PDF]

Int J Mol Sci
Song Z, Murakoshi N, Xu D, Xi B, Murakata Y, Aonuma K, Tajiri K, Ishizu T.   +7 more
europepmc   +1 more source

BET-inhibitors as sensitizers for BH3-mimetics

Aging, 2017
Ishida, Chiaki Tsuge, Karpel-Massler, Georg, Siegelin, Markus D.   +2 more
openaire   +2 more sources